753494-70-1

Upstream product

• 2272-40-4 2-phenylamino-4,6-dichloro-s-triazine 
• 371-40-4 4-fluoroaniline 
• 62-53-3 aniline 

Downstream Products

• 753494-72-3 2-phenylamino-4-(4'-fluorophenylamino)-6-(4'-acetylphenylamino)-s-triazine 
• 844476-09-1 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-furan-2-yl-propenone 
• 844476-10-4 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-pyridin-3-yl-propenone 
• 844476-04-6 1-{4-[4-(4-fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-p-tolyl-propenone 
• 844476-05-7 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-(3-methoxy-phenyl)-propenone 
• 844476-01-3 (E)-3-(3-Chloro-phenyl)-1-{4-[4-(4-fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-propenone 
• 844476-02-4 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-(2-nitro-phenyl)-propenone 
• 844476-03-5 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-(4-nitro-phenyl)-propenone 
• 844476-07-9 (E)-3-(2,5-Dimethoxy-phenyl)-1-{4-[4-(4-fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-propenone 
• 844476-08-0 (E)-1-{4-[4-(4-Fluoro-phenylamino)-6-phenylamino-[1,3,5]triazin-2-ylamino]-phenyl}-3-(3,4,5-trimethoxy-phenyl)-propenone 

Relevant academic research and scientific papers

Synthesis and antitumor evaluation of a novel series of triaminotriazine derivatives

A series of triaminotriazine derivatives (compounds 5a-f, 6a-x, and 7a-g) was designed, synthesized, and evaluated for their inhibition activities to colorectal cancer (CRC) cell lines (HCT-116 and HT-29). Most of the synthesized compounds demonstrated moderate anti-proliferatory effects on both HCT-116 and HT-29 cell lines at the concentration of 10 μM. The inhibitory activities against HCT-116 and HT-29 cell lines were discussed to develop the structure-activity relationships of this new series. Compounds 6l and 6o exhibited prominent inhibition activities toward HCT-116, with IC50s of 0.76 and 0.92 μM, respectively. The in vivo antitumor studies and pharmacokinetics of compound 6l showed that it might be a promising new hit for further development of antitumor agents.

Synthesis of pyrazolines, isoxazolines and aminopyrimidines as biological potent agents

Chalcones, 2-phenylamino-4-(4′-fluorophenylamino)-6-[4′- {3″-(phenyl/substituted phenyl /2?-furanyl/3?-pyridinyl)- 2″-propenon-1″-yl} phenylamino]-s-triazines 6a-j have been prepared from ketone 5 based on s-triazine nucleus. These chalcones 6a-j on cycli

2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE

This invention relates to an anti-dementia agent which uses a BEC 1 potassium channel inhibitor as the active ingredient. It was proved that the BEC 1 potassium channel inhibitor has an action to improve learning disorder and is useful as a preventive or therapeutic agent for diseases, preferably dementia, in which the BEC 1 potassium channel is considered to be concerned. Illustratively, it was confirmed by an in vivo test that the BEC 1 potassium channel inhibitor has an action to improve learning disorder. Also, it was found that a compound having 2,4,6-triamino-1,3,5-triazine has a BEC 1 potassium channel inhibitory action.